Li Gan, PhD, wants to find treatments to help patients with Alzheimer’s disease. Like most researchers, she’s hit a few major roadblocks.
When researchers like Gan find potential new drugs, it’s useful to test them on human cells to increase the chances that they will benefit patients. Historically, these tests have been conducted in cancer cells, which often don’t match the biology of human brain cells.
“The problem is that brain cells from actual people don’t survive well in a dish, so we need to engineer human cells in the lab,” explained Gan, senior investigator at the Gladstone Institutes. “But, that’s not as simple as it may sound.”
Many scientists use induced pluripotent stem cells (iPSCs) to address this issue. IPSCs are made by reprogramming skin cells or blood cells to become stem cells, which can then be transformed into any type of cell in the body. Gan uses iPSCs to produce brain cells, such as neurons or glial cells, because they are relevant to neurodegenerative disease.
Human brain cells derived from iPSCs offer great potential for drug screening. Yet, the process for producing them can be complicated, expensive, and highly variable. Many of the current methods produce cells that are heterogeneous, or different from one another, and this can lead to inconsistent results in drug screening. In addition, producing a large number of cells is very costly, so it’s difficult to scale up for big experiments.
A new platform developed in Gan’s lab will now allow scientists to overcome these constraints
A New Technique Is Born
“I came across a new method to produce iPSCs that was developed at Stanford,” said Michael Ward, MD, PhD, a former staff scientist in Gan’s lab who is now an investigator at the National Institutes of Health. “I thought that if our team could find a way to simplify and better control that approach, we might be able to improve the way we engineer human brain cells in the lab.”
Ward and his colleague Chao Wang, PhD, discovered a way to manipulate the genetic makeup of cells to produce thousands of neurons from a single iPSC. This meant that every engineered brain cell was now identical.
“I was truly motivated by our initial results,” said Gan, who is also a professor of neurology at UC San Francisco. “I had observed too much variability using the traditional methods, which made reproducing experiments quite problematic. So, the ability to produce homogeneous human brain cells was very exciting.”
The team further improved the technique to create a simplified, two-step process. This allows scientists to precisely control how many brain cells they produce and makes it easier to replicate their results from one experiment to the next.
Their technique also greatly accelerates the process. While it would normally take several months to produce brain cells, Gan and her team can now engineer large quantities of them within 1 or 2 weeks, and have functionally active neurons within 1 month.
The researchers realized this new approach had tremendous potential to screen drugs and to study disease mechanisms. To prove it, they tested it in their own research.
They applied their technique to produce human neurons by using iPSCs. Then, they developed a drug discovery platform and screened 1,280 compounds. Their goal is to identify the compounds that could lower levels of the protein tau in the brain, which is considered one of the most promising approaches in Alzheimer’s research and could potentially lead to new drugs to treat the disease.
“We showed that we can engineer large quantities of human brain cells that are all the same, while also significantly reducing the costs,” said Wang, Gladstone postdoctoral scholar. “This means our technology can easily be scaled up and can essentially be used to screen millions of compounds.”
A Powerful Tool for the Entire Scientific Community
“We have developed a cost-effective technology to produce large quantities of human brain cells in two simple steps,” summarized Gan. “By surmounting major challenges in human neuron-based drug discovery, we believe this technique will be adopted widely in both basic science and industry.”
Word of this useful new technology has already spread, and people from different scientific sectors have come knocking on Gan’s door to learn about it. Her team has shared the new method with scores of academic colleagues, some of whom had no experience with cell culture. So far, they all successfully repeated the two-step process to produce their own cells and facilitate scientific discoveries.
Details of this new technique were published on October 10, 2017, in the scientific journal Stem Cell Reports.
With some of the roadblocks out of the way, Gan hopes more discoveries will soon help the millions who suffer from Alzheimer’s disease and related conditions.
Learn more: Growing Human Brain Cells in the Lab
The Latest on: Drug discovery
Cloud-Based Drug Discovery Platform Market to Be Worth +13.2% by 2025 According to New Research
on June 20, 2018 at 7:24 am
Top key players profiled of in this report: IBM Corporation, Accenture PLC, Tata Consultancy Services Limited, SAS Institute Inc., BioXcel Corporation, Cloud Pharmaceuticals Inc., WuXi AppTec (Sanghai) Co. Ltd., Dassault System, Acelot, Inc. Houston, TX ... […]
Unlocking efficiency in drug discovery
on June 19, 2018 at 8:14 am
Right now, scientists are working hard to find the next blockbuster drug. In laboratories across the world, millions of molecules are being screened against challenging drug targets. Those with potential will then be chemically optimised to improve their ... […]
Robotics: Changing the Face of Drug Discovery - PharmaBoardroom
on June 19, 2018 at 7:40 am
While the automotive and electronics industries, among others, have been relatively fast in adopting robotics, pharma has been lagging behind. However, as the technology available becomes more advanced, flexible and affordable, robotics now stands as a ... […]
Novo Nordisk Inks Collab with Kallyope for Gut–Brain Axis Drug Discovery
on June 19, 2018 at 6:38 am
Novo Nordisk has announced a drug discovery collaboration with New York–based Kallyope to develop peptide therapeutics to treat obesity and diabetes. Under the terms of the agreement, the value of which was not disclosed, Kallyope will receive an up ... […]
Insilico Medicine Earns Accolades from Frost & Sullivan for Its Pioneering R&D in AI for Aging Research and Drug Discovery
on June 18, 2018 at 10:14 pm
The company has leveraged its expertise in Artificial Intelligence, Big Data analytics, and blockchain to create an ecosystem of cutting-edge solutions to support R&D for aging-related products and solutions LONDON, June 19, 2018 /PRNewswire/ -- Based on ... […]
AI set to become important component of drug discovery, development
on June 14, 2018 at 9:50 am
Despite some uncertainties around artificial intelligence in health care, one area where it is drawing significant interest is in drug discovery and development. A partnership between Swiss drugmaker Novartis and US chip maker Intel has enabled researchers ... […]
UC San Diego Launches New Center for Anti-Parasitic Drug Discovery and Development
on June 13, 2018 at 11:21 am
These children live in Bangladesh, where UC San Diego researchers are leading a clinical trial to determine if a repurposed rheumatoid arthritis drug can be used treat amebiasis and giardiasis. Image source: Flickr/IRRI Neglected tropical diseases are a ... […]
3D Human Spheroids as a Predictive Model in Drug Discovery
on June 13, 2018 at 12:58 am
In a field divided between in vivo and in vitro studies, scientists often weigh out the respective caveats before designing an experiment. While 2D in vitro experiments fall short in recapitulating the structural complexities of the human body, the ... […]
via Google News and Bing News